Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies.
暂无分享,去创建一个
[1] E. Estey,et al. Phase I/II multisite trial of optimally dosed clofarabine and low‐dose TBI for hematopoietic cell transplantation in acute myeloid leukemia , 2019, American journal of hematology.
[2] M. Maris,et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. , 2019, The Lancet. Haematology.
[3] R. Storb,et al. Allogeneic hematopoietic cell transplantation in the outpatient setting. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] J. Cerhan,et al. FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts , 2017, Hematological oncology.
[5] Sonali M. Smith,et al. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma , 2017, Journal of Hematology & Oncology.
[6] S. Novaković,et al. PHARMACOKINETIC DYNAMIC RELATIONSHIPS Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome , 2017 .
[7] G. Rosner,et al. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] D. Miklos,et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. , 2015, Blood.
[9] F. Demirkan,et al. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study , 2015, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[10] K. Stamatopoulos,et al. Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath? , 2019, Leukemia & lymphoma.
[11] A. Zelenetz,et al. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] J. Zhi,et al. Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia , 2012, Journal of clinical pharmacology.
[13] L. Rimsza,et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone , 2012, Haematologica.
[14] R. Storb,et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] R. Storb,et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.
[16] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[17] R. Storb,et al. The role of B cells in the pathogenesis of graft-versus-host disease. , 2009, Blood.
[18] R. Gale,et al. Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation , 2009, British journal of haematology.
[19] W. Weng,et al. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma , 2009, Leukemia & lymphoma.
[20] M. Sorror,et al. Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience , 2008, British journal of haematology.
[21] S. Amadori,et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. , 2008, Blood.
[22] P. Mclaughlin,et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. , 2008, Blood.
[23] M. Sorror,et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Amadori,et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. , 2007, Blood.
[25] M. Maris,et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.
[26] R. Fanin,et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study , 2007, Bone Marrow Transplantation.
[27] R. Foà,et al. FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin’s lymphoma patients treated with sequential CHOP and rituximab , 2007 .
[28] B. Labar,et al. FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma , 2007 .
[29] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Carella,et al. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease , 2007, Leukemia & lymphoma.
[31] Yeon-Hee Park,et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. , 2006, Blood.
[32] J. Ritz,et al. Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.
[33] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[34] R. Levy,et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Gascoyne,et al. Long‐term disease‐free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation , 2004, British journal of haematology.
[36] E. Kimby,et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Colombat,et al. Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.
[38] J. Byrd,et al. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia , 2004 .
[39] Catherine J. Wu,et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.
[40] Ruta Bajorunaite,et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.
[41] W. Weng,et al. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] H. Deeg,et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. , 2003, Blood.
[43] N. Schmitz,et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation , 2003, Bone Marrow Transplantation.
[44] R. Storb,et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.
[45] M. Maris,et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[46] U. Jäger,et al. Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies? , 2002, Journal of Clinical Immunology.
[47] G. Salles,et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.
[48] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[49] Cahn,et al. Allogeneic bone marrow transplantation in aggressive non‐Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database , 1999 .
[50] Anajane G. Smith,et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.
[51] M. Czuczman,et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] D. Weisenburger,et al. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] E. Abella,et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma , 1994 .
[54] R. Chopra,et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Sonali M. Smith,et al. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[56] P. Gaulard,et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de Moelle. , 1999, British journal of haematology.
[57] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.